Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan.

Witzig, Thomas E; Molina, Arturo; Gordon, Leo I; Emmanouilides, Christos; Schilder, Russell J; Flinn, Ian W; Darif, Mohamed; Macklis, Roger; Vo, Katie; Wiseman, Gregory A

Witzig, Thomas E; Molina, Arturo; Gordon, Leo I; Emmanouilides, Christos; Schilder, Russell J; Flinn, Ian W; Darif, Mohamed; Macklis, Roger; Vo, Katie; Wiseman, Gregory A.

Affiliation

Witzig TE; Department of Internal Medicine, Division of Hematology, Mayo Clinic, Rochester, Minnesota 55905, USA. thomas@mayo.edu

Cancer ; 109(9): 1804-10, 2007 May 01.

Article in En | MEDLINE | ID: mdl-17380530

Subject(s)

Antibodies, Monoclonal/therapeutic use; Antineoplastic Agents/therapeutic use; Lymphoma, B-Cell/radiotherapy; Radioimmunotherapy/methods; Yttrium Radioisotopes/therapeutic use; Antibodies, Monoclonal, Murine-Derived; Drug Resistance, Neoplasm; Humans; Immunoconjugates/therapeutic use; Lymphoma, B-Cell/drug therapy; Lymphoma, B-Cell/mortality; Neoplasm Recurrence, Local/drug therapy; Neoplasm Recurrence, Local/mortality; Rituximab

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Yttrium Radioisotopes / Lymphoma, B-Cell / Radioimmunotherapy / Antibodies, Monoclonal / Antineoplastic Agents Type of study: Clinical_trials / Prognostic_studies Limits: Humans Language: En Journal: Cancer Year: 2007 Document type: Article Affiliation country: United States Country of publication: United States

Search on Google

Add to My VHL

XML

PubMed Links